Apoptosis, a genetically controlled process of cell death, plays a central role in metazoan development and homeostasis (61, 74) . The apoptotic program is highly conserved during evolution, and striking similarities have been observed in the cell death programs of rodents, mammalian cells, Drosophila melanogaster, and Caenorhabditis elegans (28, 81, 85, 91) . In normally proliferating cells, the apoptotic program is actively suppressed or inactivated; however, withdrawal or inhibition of the apoptosis suppressor mechanisms triggers apoptotic pathways (16, 37, 86) . One mechanism by which apoptotic gene products may be prevented from executing their effect may involve direct interaction with specific proteins that act to attenuate the function of the apoptotic activators or effectors. The interaction between antiapoptotic protein Bcl-2 and proapoptotic protein Bax illustrates this point: whether a cell undergoes apoptosis or not is dependent upon the relative levels of these two proteins; an excess of Bax will trigger apoptosis, whereas an excess of Bcl-2 will prevent apoptosis (38, 66, 68, 89, 90) . Identification of other such antiapoptotic and proapoptotic protein pairs that dictate the survival of cells should enhance our understanding of the apoptosis process.
Apoptosis is characterized by cell membrane blebbing, chromatin condensation, changes in nuclear architecture, and oligonucleosome-length DNA fragmentation (87, 88) . The process of apoptotic cell death is triggered by diverse stimuli such as cytokines, withdrawal of growth factors, DNA damage, expression of oncogenes or immediate-early genes, and fluctuations in the levels of Bcl-2 family members (3, 13, 16, 37, 47, 48, 54, 71, 78, 86, 89) . Certain apoptotic stimuli can sequentially activate the basal cell death machinery composed of initiator, amplifier, and effector proteases belonging to the interleukin-1-converting enzyme (ICE) subfamily or an ICE-related family (9, 17, 21, 41, 46, 91) . Downstream targets of these proteases include the ICE subfamily proteases themselves; nuclear enzymes poly(ADP-ribose) polymerase and DNA-dependent protein kinase, which are involved in DNA repair; the nuclear protein U1 ribonucleoprotein and nuclear lamins; and cytoplasmic components such as protein kinase C␦ and cytoskeleton components such as actin (cited in reference 21). However, it is unclear whether any of these cellular components are directly linked to the morphological changes associated with apoptosis.
Prostate tissue, which is composed of androgen-dependent and -independent cells (8, 58) , provides an excellent model system for studying apoptosis. Androgen ablation in animals leads to an elevation of intracellular calcium that subsequently results in apoptosis of the androgen-dependent but not of the androgen-independent prostatic cells (11, (42) (43) (44) . However, apoptosis can be induced in androgen-independent cell cultures by artificially upregulating intracellular calcium with calcium ionophores (53, 69) or with thapsigargin (TG) (22) , an activator of the capacitative calcium channel (27, 79) . Gene expression studies of the rat ventral prostate or prostatic cells have identified a number of genes that are upregulated during apoptosis (5, 6, 43) ; however, none of these genes has been shown to be functionally responsible for causing apoptosis. Because the events subsequent to intracellular calcium elevation are common to androgen-dependent and -independent prostatic cells (69), we sought to identify immediate-early genes that are associated with apoptosis caused by the calcium ionophore ionomycin in prostatic cells. Differential hybridization studies led to the isolation and identification of a set of immediate-early genes, designated prostate apoptosis response (par) genes (69) . Further characterization of these genes confirmed that they were induced by ionomycin in androgen-independent prostate cancer cells and by castration in androgendependent cells of the rat ventral prostate (69) . Gene expression studies using rat prostatic cells revealed that one of these genes, designated par-4, is exclusively induced by apoptotic but not by growth-promoting, growth-arresting, or necrotic stimuli (69) . The deduced amino acid sequence of the product of rat par-4 cDNA predicts a leucine zipper protein with a nuclear localization signal (69) .
A cDNA clone representing the human homolog of par-4 was isolated in a parallel study (34) that used the yeast twohybrid system to identify proteins that bind to Wilms' tumor suppressor protein WT1 (7) . Inactivation of WT1 correlates with Denys-Drash syndrome, which is characterized by severe urogenital disorders and Wilms' tumor, a pediatric cancer (7, 12, 30) . This protein is expressed in the developing kidney (2) and in the adult urogenital system (59, 60) . WT1 has been shown to cause growth suppression in both Wilms' tumor and non-Wilms' tumor cells (31, 40, 49, 65) . WT1 is also implicated in apoptosis: when expressed from a constitutive promoter, WT1 confers protection from p53-dependent apoptosis (52); on the other hand, when expressed from an inducible promoter that provides relatively higher levels of the protein, WT1 is responsible for apoptosis (19) . WT1 belongs to the early growth response (EGR) family of zinc finger-containing transcription factors (75) . The C terminus of WT1 contains four Cys-His zinc finger domains with extensive homology to the zinc fingers of EGR-1 protein (23, 64) . The N terminus of WT1 has transcription regulatory functions: WT1 acts as a transcriptional repressor or activator, depending upon the promoter context and upon the wild-type or mutant status of endogenous p53 protein (50, 51, 82) . WT1 has been proposed to mediate its effects by binding, via its zinc finger domain, to the EGR-1 consensus sequence, 5Ј-GCGGGGGCG-3Ј (64, 76) ; to a (TCC) n motif (83); or to the 10-bp motif, 5Ј-GCGTGGGAG T-3Ј, for which it has the highest affinity (56) . By using reporter constructs that contain minimal promoter regions, genes of the following proteins have been identified as potential downstream targets of WT1: insulin-like growth factor 2 (15), platelet-derived growth factor A (24), insulin-like growth factor 1 receptor (84), transforming growth factor ␤ (14), colony-stimulating factor (32), insulin-like growth factor binding protein (cited in reference 56), retinoic acid receptor alpha (29) , WT1 itself (67), inhibin alpha (33) , and epidermal growth factor receptor (19) .
Characterization of WT1-Par-4 interactions by using the rat par-4 construct suggested that the Par-4 protein encoded by par-4 cDNA interacts, via its leucine zipper domain, with the zinc finger domain of the WT1 protein (34) . Furthermore, Par-4 acts as a transcriptional repressor of WT1-mediated transcriptional activation (34) . Interestingly, Par-4 neither binds to nor influences the transactivation function of EGR-1 protein (34), suggesting specificity for the Par-4-WT1 interaction. These observations suggest that par-4 function is influenced by the ability of the leucine zipper domain to interact with specific proteins and modulate their cellular functions. The present study was undertaken to determine the functional role of par-4 in apoptosis.
MATERIALS AND METHODS
Isolation of par-4 cDNA. A previously isolated 1-kb cDNA clone for par-4 (69) was used as a probe to screen approximately 100,000 clones from a rat AT-3 cell cDNA library (69) . Two cDNA clones (1.2 and 2.1 kb) were isolated and subjected to complete nucleotide sequencing by the dideoxy-nucleotide chain termination method as previously described (69) . Nucleotide sequencing showed that the two new cDNA isolates and the 1-kb cDNA clone were identical at their 3Ј overlapping ends, consistent with the fact that the cDNA library was constructed by oligo(dT) priming. The deduced amino acid sequence corresponding to par-4 predicted a protein with a leucine zipper domain beginning at amino acid 292 at its carboxy terminus. The putative leucine zipper of Par-4 protein conforms to the canonical sequence (26, 45, 57, 80) for a leucine zipper domain with a heptad repeat (abcdefg) n of hydrophobic residues at position a (i.e., amino acids 292, 299, 306, 313, 320, and 327) and with leucine (L) residues at position d (i.e., amino acids 295, 302, 316, 323, and 330), with the exception of the hydrophobic residue methionine (M) at position d (amino acid 309) in the third repeat. The deduced amino acid sequence also predicts a bipartite localization sequence (73, 77) , RKGKGQIEKRKLREKRR, at amino acids 137 through 153 of the Par-4 protein. Moreover, the first methionine codon (ATG) fulfills the Kozak criterion (RNNATGG, where N represents nucleotide A, C, T, or G and R represents an A or a G) (39) for an initiator codon (nucleotide sequence in GenBank).
Plasmid constructs and deoxyoligomers. To obtain construct CMV-par-4, the par-4 cDNA in vector pcDNAII was digested with XbaI, which cleaves in the vector and at about 1.2 kb in the par-4 cDNA. This fragment includes the translation initiation codon at nucleotide 67 and the translation termination codon at nucleotide 1063. This XbaI fragment of par-4 cDNA was subcloned into the XbaI site of pRc/CMV vector (Invitrogen, San Diego, Calif.). This construct encodes a 1.2-kb RNA species and a full-length (i.e., about 38 kDa) Par-4 protein. The CMV-par-4.⌬CTH (carboxy terminus half deletion mutant) was prepared by first digesting pcDNAII-par-4 cDNA with HincII to delete nucleotides 541 through 1267 in par-4 cDNA and religating the plasmid, then digesting the plasmid with EcoRI, which cleaves at about 1.4 kb and in the vector, and finally subcloning the EcoRI fragment into pCB6 ϩ (15, 50) . CMV-Par-4.⌬CTH therefore expresses an approximately 700-bp RNA species or the amino-terminal half (i.e., about 18 kDa) of the Par-4 protein. The construction of CMV-par-4.⌬leu.zip (previously designated pCMV-par-4 1-267 ) has been described previously (34) . This construct encodes an 862-bp RNA species and an approximately 30-kDa protein.
To obtain the CMV-leu.zip construct, we first used PCR with CMV-par-4 as a template and upstream and downstream primers to synthesize DNA corresponding to the par-4 leucine zipper sequence. The upstream primer, 5Ј-TTTTAAG CTTGGAACATGGCAG 784 GCTTCAGTAGACACAACAG-3Ј, contained a built-in HindIII site (underlined), a Kozak consensus sequence (39) flanking the ATG translation initiation sequence (shown in italics), and the indicated sequence downstream of nucleotide G at position 784 (in boldface). The downstream primer was 5Ј-ACACAGAACCAAGAGGCATCA-3Ј, corresponding to nucleotides 1314 through 1294 (i.e., downstream of the translation stop codon at nucleotide 1063) in par-4 cDNA. The fragment was digested with HindIII to cleave the built-in site in the upstream primer and with XbaI to cleave at an internal XbaI site at nucleotide 1173 in par-4 cDNA; it was then subcloned directionally into the HindIII and XbaI sites of pCB6 ϩ . This construct encodes an approximately 400-bp RNA species and an approximately 10-kDa protein species. The coding region contained within each par-4 cDNA fragment in the above constructs is shown in Fig. 1 . We also used a cytomegalovirus promoterdriven expression construct for WT1, CMV-WT1 (from Frank Rauscher, Wistar Institute, Philadelphia, Pa.) (15) .
For inhibition of par-4 expression, we used an antisense (AS) deoxyoligomer (5Ј-ATAGCCGCCGGTCGCCATGTT-3Ј) that is complementary to the region spanning the initiation codon (underlined). For a control, we used a non-sense (NS) oligomer (5Ј-CCGTGTCTGATCTTCGTGCGT-3Ј). In view of the calculated long half-life (approximately 30 h) of the Par-4 protein, the oligomers were added to the cells 30 h before, and also at the time of, exposure to TG. The highest concentration of each oligomer that did not inhibit the growth of the cells, as determined by [ 3 H]thymidine uptake studies, was 10 M. Cell culture, exogenous activators, and transfection of cells. Rat androgenindependent prostate cancer cell line AT-3 cells (53) and human androgenindependent prostate cancer cell line PC-3 cells (36) were kindly provided by John Isaacs (Johns Hopkins University, Baltimore, Md.). Human melanoma cell line A375-C6 (18) has been previously described (62, 63) . AT-3, PC-3, and A375-C6 cells were cultured in RPMI 1640 medium supplemented with 10% serum. TG was purchased from Calbiochem Corp. (La Jolla, Calif.). Transfection experiments were performed as previously described (1, 35, 70) , and transfectants were selected in culture medium supplemented with 300 g of G418 sulfate (Life Technologies, Inc., Gaithersburg, Md.) per ml. Human recombinant interleukin 1␤ (IL-1␤; specific activity, 1.8 ϫ 10 7 U/mg), a gift from Craig Reynolds, Biological Response Modifiers Program, National Cancer Institute (Frederick, Md.), was used at a final concentration of 100 U/ml.
Assays for growth inhibition and apoptosis. To quantify the effect of IL-1 on growth inhibition or that of TG on apoptosis, the cells were grown in the absence or presence of IL-1 for 48 h or in the absence or presence of TG for 24 h. Thereafter, the cells were subjected either to [ 3 H]thymidine incorporation assays to determine growth inhibition (54, 62, 63) or to terminal transferase-mediated dUTP-digoxigenin end labeling (TUNEL) (25) by using the ApopTag kit (Oncor, Gaithersburg, Md.) to determine the number of apoptotic cells, as described previously (54) .
Anti-Par-4 antibody. The 1.4-kb EcoRI fragment of par-4 cDNA was subcloned into the EcoRI site in the polylinker region of pRSET vector (Invitrogen Corp.) so as to place the cDNA downstream in-frame of the His 6 EK-tag sequence and to obtain construct pRSET-tag-par-4. This construct was transformed into Escherichia coli BL21(DE3) (Novagen, Madison, Wis.), and transformant bacterial cells were used for preparation and purification of the tag-Par-4 fusion protein. A polyclonal antibody against the fusion protein was generated in rabbits by using standard procedures. The immunoglobulin G subunit of the antibody was purified by affinity chromatography by using a protein A-protein G column, and the antibody was used at a final concentration of 0.1 g/ml. To test the specificity of the antibody, Western blot experiments were performed by using Par-4 antibody (0.1 g/ml) that had been preincubated for 1 h with 10 g of Par-4 peptide per ml, corresponding to amino acids 1 to 332 (Santa Cruz Biotechnology, Inc.), or with 20 g of EGR-1 (nonspecific) peptide per ml, or with 0.1 g of preimmune rabbit immunoglobulin G antibody per ml.
Western (immunoblot) analysis. Whole-cell protein extracts were prepared and, unless otherwise indicated, 20-g amounts of each protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred to nylon membranes, which were subsequently probed with the antiPar-4 antibody or the anti-␤-actin antibody (Sigma Chemical Co.) and then incubated with 125 I-protein A, as described previously (70). Northern analysis. Isolation of total RNA and Northern analysis were performed as described previously (62, 63, 69) . The probe for par-4 was prepared with the 2.1-kb cDNA fragment from the pcDNAII-par-4 clone that was isolated from the cDNA library. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe has been described previously (70) . Prehybridization and hybridization were performed overnight at 62°C, and blots were washed in SSC at a final stringency of 0.1ϫ (15 mM NaCl plus 1.5 mM sodium citrate; pH 7), at 62°C, as described previously (62, 63) . Equal loading of RNA was verified by probing blots with cDNA for GAPDH, and fold induction was calculated after densitometric scanning and normalizing the hybridization signal with respect to GAPDH.
Nucleotide sequence accession number. The nucleotide and deduced amino acid sequences of the 2.1-kb rat AT-3 cell cDNA have been deposited in GenBank under accession no. U05989.
RESULTS

Induction of par-4 in prostatic cells by apoptotic stimuli.
To study the induction kinetics of par-4, we exposed AT-3 cells for various intervals of time to TG, an agent which has been shown to elevate intracellular calcium and cause apoptosis in these cells (22) . Total RNA was then prepared and subjected to Northern blot analysis. As seen in Fig. 2A , untreated AT-3 cells expressed modest levels of par-4 RNA. When the cells were exposed to TG for 0.5 h, the par-4 RNA levels were similar to the basal levels in untreated cells; subsequently, TG induced a fourfold increase in par-4 RNA in 1 h, and sustained increased levels (about five-to eightfold over basal levels) of par-4 RNA were maintained for at least 24 h (Fig. 2A) .
To study Par-4 protein expression, we used a rabbit polyclonal antibody raised against Par-4 protein as described in Materials and Methods. To ascertain the specificity of this antibody, we performed Western blots by using the Par-4 antibody or preimmune antibody as a control. In addition, we used the Par-4 antibody after preincubating it with Par-4 peptide to block the anti-Par-4 activity or after preincubating it with EGR-1 peptide as a corresponding control. When wholecell protein extracts from AT-3, PC-3, or A375-C6 cells were examined by Western blot analysis by using the Par-4 antibody, a relatively strong band was seen at about 38 kDa and much weaker bands were seen at 20 to 25 kDa and 10 to 15 kDa (Fig.  2B) . The size of the strong band (38 kDa) was consistent with that predicted for Par-4 protein from the deduced amino acid sequence. Neither the preimmune antibody nor the Par-4 antibody that was preincubated with the Par-4 peptide showed any of these bands (Fig. 2B) . When the blots were probed with the Par-4 antibody that had been preincubated with EGR-1 peptide (Fig. 2B) , the reactivities of the antibody with the 38-kDa or the weaker protein species were found to be unaffected. Together, these data suggest that the Par-4 antibody specifically detected Par-4 protein species of 38 kDa and that the relatively weaker lower-molecular-size bands most likely represent breakdown products of Par-4 protein.
The induction kinetics of Par-4 protein in AT-3 cells were similar to those for par-4 RNA. Untreated AT-3 cells expressed modest levels of Par-4 protein (Fig. 2C) . When exposed to TG, AT-3 cells showed an induction of the Par-4 protein within 1 h of exposure and enhanced levels of Par-4 protein were maintained for at least 24 h (Fig. 2C) . These findings suggest a good coordination between the regulation of par-4 at the RNA and protein levels.
Par-4 is required for apoptosis in AT-3 cells. Because modest levels of Par-4 protein were expressed in diverse organs and cultured cells, including those that do not show spontaneous apoptosis (4), it was obvious that basal levels of Par-4 protein were not sufficient to cause apoptosis. However, it was possible that Par-4 was required to cause the apoptotic death of cells subjected to exogenous stimuli that perturbed normal cellular processes. Toward the goal of determining the function of Par-4 protein in apoptosis, we examined whether inhibition of the expression of Par-4 results in inhibition of apoptosis.
To inhibit the expression of par-4, we used an AS oligomer that was directed against the initiation codon of par-4. For a control, we used an NS oligomer that was distinct in sequence but similar in length and GC content to the AS oligomer. We ]thymidine incorporation assays were performed. These assays indicated that the maximal concentration of the oligomers that did not inhibit the growth of the cells in these exposure periods was 10 M (data not shown).
Next, to ascertain that the AS oligomer but not the NS oligomer inhibited par-4 expression in AT-3 cells, the cells were exposed to the oligomers for 30 h. The culture medium was then replaced with fresh medium that contained either the AS or NS oligomer or one of the two oligomers plus TG, and the cells were exposed for an additional 36 h. A separate set of flasks was left untreated or was treated with TG alone for 36 h. Whole-cell protein extracts were then prepared and subjected to Western blot analysis for Par-4 protein. As seen in Fig. 3A , untreated AT-3 cells showed a basal level of Par-4 expression, which was induced upon treatment with TG. Pretreatment with the NS oligomer did not inhibit the ability of TG to induce Par-4 expression. By contrast, treatment with the AS oligomer strongly inhibited Par-4 induction by TG and the levels dropped below the basal levels in untreated cells (Fig. 3A) . These results on the inhibition of par-4 expression with the AS oligomer were reproduced in a Northern blot analysis for par-4 (data not shown). To ascertain that the AS oligomer did not generally block gene expression, Northern blots were probed for expression of par-1 (69), c-myc, or ␤-actin, and the data indicated that neither the AS nor the NS oligomer inhibited the expression of par-1, c-myc, or ␤-actin in AT-3 cells (data not shown). These findings indicated that the AS oligomer preferentially inhibited the expression of par-4.
We then studied the effect of the AS or NS oligomer on the apoptotic response of AT-3 cells to TG. The cells were left untreated or were pretreated with AS or NS oligomer for 30 h. The medium from untreated cells was then replaced with fresh medium for an untreated control or with TG alone, that from AS-treated cells was replaced with AS oligomer plus TG, and that from NS-treated cells was replaced with NS oligomer plus TG. After 36 h, the cells were subjected to TUNEL to determine the number of apoptotic cells. As seen in Fig. 3B , untreated cells showed Ͻ5% TUNEL-positive nuclei, whereas treatment with TG produced 25 to 30% TUNEL-positive nu- clei. Cells that were treated with AS oligomer plus TG showed about 5% TUNEL-positive nuclei, indicating a diminution in the number of apoptotic cells as compared to those treated with TG alone (Fig. 3B) . By contrast, cells that were treated with NS oligomer plus TG showed about 30% TUNEL-positive nuclei (Fig. 3B) . These findings suggest that the AS oligomer inhibits the ability of TG to cause apoptosis.
Par-4 sensitizes PC-3 cells to apoptotic stimuli. Next, we determined whether ectopic overexpression of Par-4 causes apoptosis on its own or enhances the apoptotic response to TG. These studies used prostate cancer cell line PC-3 cells because compared to AT-3 cells the PC-3 cells showed lower basal levels of Par-4 protein (see Fig. 2B ). PC-3 cells were transfected with vector pCB6 ϩ , CMV-par-4, CMV-par-4.⌬CTH, or CMV-par-4.⌬leu.zip (constructs described in Materials and Methods and shown in Fig. 1 ), and transfected cell lines were selected with G418 sulfate. Similar numbers of transfected clones (150 Ϯ 30) were seen with the vector or the par-4 constructs, providing evidence that par-4 was not inhibitory on its own. Next, approximately 100 transfected clones from each independent transfection experiment were pooled to obtain the following cell lines: vector.L1, -.L2, and -.L3; CMV-par-4.L1, -.L2, and -.L3; CMV-par-4.⌬CTH.L1, -.L2, and -.L3; and CMV-par-4.⌬leu.zip.L1, -.L2, and -.L3. We then determined by Western blot analysis whether the transfected cells expressed wild-type or mutant Par-4 protein, and data representative of the transfected cell lines are shown in Fig.  4A . Cell line vector.L2 that was transfected with the vector showed a low level expression of the endogenous 38-kDa Par-4 protein (Fig. 4A) . On the other hand, transfected cell line CMV-par-4.L2 showed strong expression of 38-kDa Par-4 protein (Fig. 4A) . Transfected cell lines CMV-par-4.⌬CTH.L2 and CMV-par-4.⌬leu.zip.L2 did not show any change in the basal level of the endogenous Par-4 species but showed expression of an 18-kDa and a 30-kDa mutant Par-4 species, respectively (Fig. 4A) , consistent with the size expected from the cDNA of the corresponding par-4 mutant constructs.
To study the effect of enhanced expression of par-4 on TGinducible apoptosis in the PC-3 cell background, the transfected cell lines (which were pools of transfected clones) were left unexposed or were exposed to TG for 24 h and then subjected to TUNEL. Cultures of the transfected PC-3 cells that were left unexposed to TG did not show TUNEL-positive cells, indicating that overexpression of par-4 was not sufficient on its own to induce apoptosis. When exposed to TG for 24 h, PC-3 cells that were transfected with the vector, CMV-par-4.⌬CTH, or CMV-par-4.⌬leu.zip showed 2 to 8% TUNELpositive cells (Fig. 4B) . On the other hand, PC-3 cells transfected with CMV-par-4 showed 20 to 30% TUNEL-positive cells (Fig. 4B ). This increase in the number of TUNEL-positive cells in PC-3/CMV-par-4 cultures was statistically significant (P Ͻ 0.001 by the Student t test). These findings suggest that the CMV-par-4 construct that overexpresses par-4, but not the par-4 mutant constructs, confers enhanced sensitivity to TGinducible apoptosis in PC-3 cells. CMV-par-4 and CMV-par-4.⌬leu.zip, or with these plasmids separately, and we selected transfected clones by using G418 sulfate. The CMV-par-4.⌬leu.zip construct was included as a control in these experiments. About 150 individual clones from each experiment were pooled to obtain transfected cell lines. The cell lines were then grown in the presence or absence of TG for 24 h and subjected to TUNEL assays. As seen in Fig.  5 , PC-3 cells transfected with CMV-par-4.⌬leu.zip, CMVpar-4, or CMV-leu.zip showed about 10, 30, or Ͻ3% apoptotic cells, respectively, when treated with TG. PC-3 cells that were cotransfected with CMV-par-4 plus CMV-leu.zip showed about 15% apoptotic cells, whereas PC-3 cells cotransfected with CMV-par-4 plus CMV-par-4.⌬leu.zip showed about 30% apoptotic cells (Fig. 5) . Thus, cotransfection with the leucine zipper-encoding domain of par-4 abrogated the ability of ectopic par-4 to enhance apoptosis, whereas the CMV-par-4.⌬leu.zip construct that encodes the leucine zipperless mutant of Par-4 did not alter the ability of ectopic par-4 to enhance apoptosis. These findings suggest that the effects of ectopically overexpressed par-4 can be reversed in a specific manner; thus, enhanced apoptosis in the par-4-transfected cells is due primarily to par-4 overexpression and is not a secondary effect resulting from the selection of a supersensitive transfected population.
Ectopic coexpression of the leucine zipper domain rescues transfected cells from
Ectopic overexpression of Par-4 enhances apoptosis in melanoma cells. Our previous study (54) showed that TG induces apoptosis in human melanoma cell line A375-C6 cells. To ascertain that enhanced apoptosis mediated by enhanced expression of par-4 is not restricted to prostate cells, we transfected A375-C6 cells with the vector, the CMV-par-4 construct, or the CMV-par-4.⌬leu.zip construct (shown in Fig. 1 ) and selected the transfectants with G418 sulfate. These transfection experiments produced similar numbers of transfected clones (200 Ϯ 50), suggesting that ectopic expression of these constructs was not toxic to the cells. About 200 clones from each experiment were pooled to obtain transfected cell lines for each construct. To ascertain expression of the transfected plasmids, whole-cell protein extracts were prepared from the cell lines and subjected to Western blot analysis. As seen in Fig. 6A , A375-C6 cells that were transfected with vector showed low basal levels of Par-4 protein. On the other hand, cell lines CMV-par-4.L1 and CMV-par-4.L2 that were transfected with CMV-par-4 showed enhanced expression of the 38-kDa Par-4 protein (Fig. 6A ). Cells transfected with CMVpar-4.⌬leu.zip showed expression of an approximately 30-kDa protein species (Fig. 6A) , corresponding to the coding region of the par-4.⌬leu.zip cDNA fragment in the construct.
The transfected A375-C6 cell lines then were either left unexposed or were exposed to TG for 24 h and subjected to TUNEL assays. As seen in Fig. 6B , cell lines transfected with the vector or CMV-par-4.⌬leu.zip construct showed about 10% apoptotic cells with TG. On the other hand, cell lines CMV-par-4.L1 or CMV-par-4.L2 that were transfected with the CMV-par-4 construct showed about 50% apoptotic cells when exposed to TG (Fig. 6B) . These findings suggested that ectopic expression of full-length par-4 was required to enhance the apoptotic response to TG.
Our previous studies indicated that IL-1 causes G 1 phase growth arrest but no apoptosis in A375-C6 cells (55, 70) . To determine whether overexpression of par-4 leads to enhanced susceptibility to growth-arresting signals, we examined whether the transfected A375-C6 cell lines were differentially responsive to IL-1. The cell lines transfected with the vector, CMVpar-4, or CMV-par-4.⌬leu.zip were left unexposed or exposed to IL-1 for 48 h and then subjected to [ overexpression of CMV-par-4 or the deletion mutant does not confer enhanced susceptibility to IL-1-inducible growth arrest.
WT1 abrogates the growth-inhibitory action of TG, and cotransfection with Par-4 partially overcomes the WT1 effect. The results described above show that the leucine zipper domain of Par-4 plays an important role in the apoptotic action of TG. Because our parallel studies on the Par-4 interaction with WT1 suggested that Par-4 binds to WT1 via its leucine zipper motif (34), we tested the effect of ectopic WT1 overexpression on Par-4-inducible apoptosis. A375-C6 cells were transfected separately with the vector, CMV-WT1, CMV-par-4, or CMVpar-4.⌬leu.zip or were cotransfected with CMV-WT1 plus CMV-par-4 or with CMV-WT1 plus CMV-par-4.⌬leu.zip. Transfected clones were selected with G418 sulfate, and pools of about 100 transfected clones were maintained as cell lines. The number of G418-resistant transfected clones obtained with the CMV-WT1 plasmid was about 60% lower than that seen with the vector, CMV-par-4, or CMV-par-4.⌬leu.zip. Interestingly, cotransfection with CMV-par-4 but not with CMVpar-4.⌬leu.zip restored the number of transfected clones to about 90% of that seen with the vector. The effect of ectopic overexpression of these plasmids on the growth of A375-C6 cells was studied over a period of 72 h by [ (Fig. 7A) , suggesting that WT1 impeded the growth of A375-C6 cells. However, cultures of cells that were cotransfected with CMV-WT1 plus CMV-par-4 showed much faster growth than those cotransfected with CMV-WT1 plus CMVpar-4.⌬leu.zip (Fig. 7A) . These results suggest that Par-4 but not the leucine zipperless mutant of Par-4 can partially restore the growth rate of WT1-transfected cells.
Next, we examined the effect of TG, which causes apoptosis, on the growth of transfected A375-C6 cells. The cells were either left untreated or were treated with TG for 24 h and then subjected to TUNEL assays. As seen in Fig. 7B , cells transfected with the vector or CMV-par-4.⌬leu.zip showed about 15% apoptosis with TG. Cells transfected with CMV-WT1 or those cotransfected with CMV-WT1 plus CMV-par-4.⌬leu.zip showed about 3% apoptosis with TG, whereas those transfected with CMV-par-4 showed about 45% apoptosis (Fig. 7B) . On the other hand, cells transfected with CMV-WT1 plus CMV-par-4 showed about 35% apoptosis with TG (Fig. 7B ). These differences in the apoptotic response to TG were statistically significant (P Ͻ 0.001 by Student t test) and suggest that ectopic WT1 abrogates the apoptotic action of TG and that cotransfection with Par-4 but not with a leucine zipperless mutant of Par-4 partially restores susceptibility to TG. Because WT1 binds to the leucine zipper domain of Par-4 (34), the reversal of WT1 action by Par-4 is most likely due to the interaction of these two proteins. By contrast, when the cells were stably cotransfected with constructs that express EGR-1 (which does not bind to the Par-4 protein [34] ) and Par-4, the transfectants showed an additive effect in enhancing the apoptotic response to TG (55a).
We also examined the effect of WT1 and Par-4 on the growth-arresting action of IL-1. A375-C6 transfectant cells were either left untreated or treated with IL-1 for 48 h and then subjected to [ Fig. 7C) . However, cells transfected with CMV-WT1 plus CMV-par-4 showed about 50 to 60% growth inhibition with IL-1 (Fig. 7C) . These statistically significant (P Ͻ 0.001 by Student t test) differences in growthinhibitory response to IL-1 suggest that ectopic WT1 enhances the growth-inhibitory action of IL-1 and that cotransfection with Par-4 but not with a leucine zipperless mutant of Par-4 abrogates the effect of WT1. These findings suggest that Par-4 does not alter the growth-arresting action of IL-1 but rescues the cells from WT1-mediated enhanced growth arrest. Thus, Par-4 acts to reverse the growth-arresting and antiapoptotic action of WT1 and enhances stimulus-dependent apoptosis.
DISCUSSION
Although recent studies (cited in reference 54) have functionally linked the products of a number of immediate-early genes to apoptosis in various cell types, such findings were not available for prostatic cells. The results of the present study show that Par-4, an immediate-early gene product (69) , is an example of a novel protein that is required for apoptosis in prostatic cells. Par-4 is induced in the rat ventral prostate tissue after castration (4) and in rat AT-3 cells by apoptotic stimuli; AS oligomers, which specifically inhibit Par-4 expression, abrogate TG-inducible apoptosis in AT-3 cells. Because castration-inducible apoptosis (11), Par-4 induction in the rat ventral prostate after castration (69) , and TG-inducible apoptosis in AT-3 cells (22) are all mediated by intracellular calcium elevation, these findings establish a link between Par-4 induction and apoptosis resulting from the calcium elevation-dependent pathway(s). However, Par-4 expression is not sufficient on its own to cause apoptosis, as is evident from the facts that the rat ventral prostate in intact animals does not show extensive apoptosis despite modest constitutive expression levels of Par-4 protein (4), that Par-4 is expressed in almost all organs from a normal animal examined (4) , that constitutive levels of Par-4 protein were detected by immunocytochemistry studies of freshly seeded AT-3 cell cultures that do not undergo apoptosis (55a), and that ectopic overexpression of Par-4 in prostate cancer cells and melanoma cells did not produce spontaneous apoptotic cells (this study). Nonetheless, Par-4 sensitizes cells to the action of apoptotic stimuli: ectopic overexpression of Par-4 sensitizes prostate cancer cells and melanoma cells to TG-inducible apoptosis (this study) and sensitizes cloned rat embryo fibroblasts (20) to apoptosis upon serum withdrawal (55a). These observations are consistent with a proapoptotic role for Par-4 protein and further suggest that Par-4 function may not be solely restricted to the intracellular calcium elevation-dependent pathway(s). Interestingly, another recent study has shown that Par-4 can interact via its leucine zipper with the zinc finger domain of the atypical protein kinase PKC-zeta and that this interaction causes an inhibition of PKC-zeta-dependent cell survival functions and leads to apoptosis (14) . Further studies are necessary to identify other signal transduction pathways in which Par-4 induction is linked to apoptosis. Because the Par-4 protein is expressed in a wide spectrum of unaffected tissues (4), it is necessary to determine whether, like the proapoptotic Bak protein that is also widely expressed (10, 37), Par-4 is required for, or confers enhanced susceptibility to, apoptosis in other experimental model systems.
To identify the functional domains of the Par-4 protein that are responsible for apoptosis, we used various deletion mutants of Par-4. These studies were performed with two different cell lines, PC-3 prostate cancer cells and A375-C6 melanoma cells, to ensure that the observations were not biased by celltype-specific factors. The results of these studies revealed that Par-4 mutants that lacked the leucine zipper domain were unable to enhance the apoptotic response to TG, implying that the leucine zipper domain was important for Par-4 function. These observations were corroborated by the finding that CMV-leu.zip, which encodes the leucine zipper domain of Par-4, but not CMV-par-4.⌬leu.zip, which encodes the leucine zipperless mutant of Par-4, rescued the cells from a Par-4-mediated growth-inhibitory response to TG. The leucine zipper domain probably binds to proteins that enhance or inhibit Par-4-mediated apoptosis, and the net response (i.e., enhanced apoptosis or abrogation of apoptosis) to apoptotic stimuli may depend on the levels, expression kinetics, and cellular distribution and compartmentalization of these proteins. One reasonable explanation for the inhibition of Par-4 function by its own leucine zipper domain suggests that the leucine zipper domain adequately inhibited Par-4 binding with other interactive proteins involved in producing stimulus-dependent apoptosis. The identification of endogenous protein partners of Par-4 involved in producing apoptosis should reveal the mechanism by which Par-4 promotes apoptosis. Alternatively, however, it is possible that the ectopically expressed leucine zipper domain may have abrogated Par-4 function by directly binding to the leucine zipper domain of the intact Par-4 protein.
Because our parallel study showed that Par-4 binds to WT1 (34), we used ectopic coexpression of Par-4 and WT1 driven by a constitutive promoter to determine whether Par-4 will rescue the cells from WT1 action. Previous studies have indicated that the ability of WT1 to cause apoptosis or to protect from apoptosis in transfected cells is dependent upon the WT1 protein levels (19, 52) . When WT1 is expressed from a constitutive promoter, relatively low levels of WT1 protein are produced, resulting in protection from apoptosis (52) . By contrast, when WT1 is expressed from an inducible promoter, higher levels of WT1 are produced, resulting in apoptotic cell death (19) . In the present study, WT1 expressed from a constitutive promoter inhibited the growth of A375-C6 cells and Par-4 but not a leucine-zipperless mutant of Par-4 rescued the cells from the growth-inhibitory effect of WT1. Moreover, WT1 enhanced the growth-arresting action of IL-1 in A375-C6 cells, and fulllength Par-4 but not the leucine-zipperless mutant of Par-4 rescued the cells from WT1-enhanced growth arrest. By using TUNEL, we confirmed that neither IL-1 nor WT1 alone can cause apoptosis in A375-C6 cells (data not shown); thus, growth inhibition by these reagents results from growth arrest. On the other hand, ectopic expression of WT1 blocked TGinducible apoptosis and cotransfection with Par-4 but not with the leucine zipperless mutant of Par-4 rescued the cells from WT1 action and enhanced TG-inducible apoptosis. Together, these findings suggest that Par-4 rescues the cells from WT1-inducible growth arrest and sensitizes the cells to TG-inducible apoptosis. These results are consistent with a causal role for Par-4 in activator-driven apoptosis. The requirement of the leucine zipper domain of Par-4 for reversal of WT1 function underscores the importance of Par-4-WT1 binding for regulation of apoptosis in the cotransfected cells. Thus, WT1 is a novel example of a protein partner of Par-4 that blocks both cell growth and apoptosis and whose actions are reversed by Par-4. Unlike WT1, which shows tissue-restricted expression (59, 60, 72) , Par-4 protein is ubiquitously expressed (this study; 34) and is found in all of the organs in which WT1 is expressed (4) . Further studies are under way to determine the physiolog-ical consequences of WT1-Par-4 interaction in tissues in which both proteins are coexpressed.
